Not actual patient.
For your HBV patients
HEPATITIS DELTA
adds layers of risk for disease progression1
Hepatitis D is the most severe, potentially underdiagnosed form of chronic viral hepatitis with no FDA-approved treatment.1-3
See burden of diseaseHepatitis D is the most severe, potentially underdiagnosed form of chronic viral hepatitis with no FDA-approved treatment.1-3
See burden of disease
Experts recommend screening hep B patients with certain key risk factors4
Experts recommend screening hep B patients with certain key risk factors4
TESTING & DIAGNOSIS
Up to
80%
Up to 80% of chronic hep D patients in the US develop cirrhosis and liver failure within 5‑10 years1
UP TO
80%
of chronic hep D patients in the US develop cirrhosis and liver failure within 5-10 years1
Burden of Disease
Persons from endemic regions are the largest group at risk of hep delta5
Persons from endemic regions are the largest group at risk of hep delta5
ENDEMIC AREAS
References: 1. Centers for Disease Control and Prevention. Hepatitis D questions and answers for health professionals. Updated March 9, 2020. Accessed August 9, 2021. https://www.cdc.gov/hepatitis/hdv/hdvfaq.htm 2. World Health Organization. Hepatitis D fact sheet. Updated July 28, 2021. Accessed August 9, 2021. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d 3. Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011–2016. Clin Infect Dis. 2019;69(4):709-712. doi:10.1093/cid/ciz001 4. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. doi:10.1002/hep.29800 5. Toy M, Ahishalı E, Yurdaydın C. Hepatitis delta virus epidemiology in the industrialized world. AIDS Rev. 2020;22:203-212. doi:10.24875/AIDSRev.20000056
